- Home
- LEU vs PLRX Comparison
LEU vs PLRX Comparison
Compare LEU & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- PLRX
- Stock Information
- Founded
- LEU 1998
- PLRX 2015
- Country
- LEU United States
- PLRX United States
- Employees
- LEU N/A
- PLRX N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- PLRX Health Care
- Exchange
- LEU Nasdaq
- PLRX Nasdaq
- Market Cap
- LEU 1.2B
- PLRX 641.5M
- IPO Year
- LEU 1998
- PLRX 2020
- Fundamental
- Price
- LEU $74.01
- PLRX $11.60
- Analyst Decision
- LEU Buy
- PLRX Strong Buy
- Analyst Count
- LEU 2
- PLRX 7
- Target Price
- LEU $92.00
- PLRX $40.50
- AVG Volume (30 Days)
- LEU 555.8K
- PLRX 544.2K
- Earning Date
- LEU 02-06-2025
- PLRX 02-26-2025
- Dividend Yield
- LEU N/A
- PLRX N/A
- EPS Growth
- LEU 50.42
- PLRX N/A
- EPS
- LEU 4.70
- PLRX N/A
- Revenue
- LEU $394,000,000.00
- PLRX N/A
- Revenue This Year
- LEU $25.25
- PLRX N/A
- Revenue Next Year
- LEU $5.68
- PLRX N/A
- P/E Ratio
- LEU $15.80
- PLRX N/A
- Revenue Growth
- LEU 14.94
- PLRX N/A
- 52 Week Low
- LEU $33.51
- PLRX $10.22
- 52 Week High
- LEU $118.36
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- LEU 50.64
- PLRX 39.38
- Support Level
- LEU $68.10
- PLRX $11.02
- Resistance Level
- LEU $74.66
- PLRX $12.70
- Average True Range (ATR)
- LEU 5.12
- PLRX 0.83
- MACD
- LEU 0.36
- PLRX -0.16
- Stochastic Oscillator
- LEU 46.52
- PLRX 17.93
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.